NCT05082233View on ClinicalTrials.gov

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

March 6, 2022

Primary Completion Date

August 3, 2023

Study Completion Date

August 3, 2023

Conditions
Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Interventions
DRUG

SHR7280 tablets

Treatment group A:SHR7280 tablets ; 300mg BID； Treatment group B:SHR7280 tablets ; 200mg BID； Treatment group C:SHR7280 tablets ; 200mg QD； Treatment group D:SHR7280 tablets ; 400mg BID；

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY